Inhibition of nonsmall cell lung cancer cell migration by protein arginine methyltransferase 1-small hairpin RNA through inhibiting epithelial-mesenchymal transition, extracellular matrix degradation, and Src phosphorylation in vitro

Chinese Medical Journal

Volumn 128, Issue 9, 2015, Pages 1202-1208

  Zhang, Ting ^a   Cui, Ge ^a   Yao, Yun Liang ^a   Guo, Yue ^a   Wang, Qi Chun ^a   Li, Xi Ning ^a   Feng, Wen Ming ^a  

^a HUZHOU UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Extracellular matrix degradation; Migration; Nonsmall cell lung cancer; Protein arginine methyltransferases 1; Src

Indexed keywords

FOCAL ADHESION KINASE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; PROTEIN KINASE B; SHORT HAIRPIN RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; SCLEROPROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL LINE; CELL MOTION; ENZYMOLOGY; GENETICS; METABOLISM; PHYSIOLOGY;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX PROTEINS; HUMANS; PROTEIN-ARGININE N-METHYLTRANSFERASES; RNA, SMALL INTERFERING;

EID: 84929087898     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.4103/0366-6999.156126     Document Type: Article

References (25)

1. Elakoum R, Gauchotte G, Oussalah A, Wissler MP, Clement-Duchene C, Vignaud JM, et al. CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features. Biochimie 2014;97:210-8.
2. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011;128:562-73.
3. Mathioudaki K, Scorilas A, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, et al. Clinical evaluation of PRMT1 gene expression in breast cancer. Tumour Biol 2011;32:575-82.
4. Wang S, Tan X, Yang B, Yin B, Yuan J, Qiang B, et al. The role of protein arginine-methyltransferase 1 in gliomagenesis. BMB Rep 2012;45:470-5.
5. Papadokostopoulou A, Mathioudaki K, Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E, et al. Colon cancer and protein arginine methyltransferase 1 gene expression. Anticancer Res 2009;29:1361-6.
6. Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. Br J Cancer 2008;99:2094-9.
7. Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer 2013;13:37-50.
8. Gu Z, Gao S, Zhang F, Wang Z, Ma W, Davis RE, et al. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J 2012;446:235-41.
9. Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 2005;18:263-72.
10. Boisvert FM, Côté J, Boulanger MC, Richard S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2003;2:1319-30.
11. Huang S, Litt M, Felsenfeld G. Methylation of histone H4 by arginine methyltransferase PRMT1 is essential in vivo for many subsequent histone modifications. Genes Dev 2005;19:1885-93.
12. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-18.
13. Xiao D, He J. Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2010;2:154-9.
14. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
15. Görögh T, Beier UH, Bäumken J, Meyer JE, Hoffmann M, Gottschlich S, et al. Metalloproteinases and their inhibitors: Influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck 2006;28:31-9.
16. Ali-Labib R, Louka ML, Galal IH, Tarek M. Evaluation of matrix metalloproteinase-2 in lung cancer. Proteomics Clin Appl 2014;8:251-7.
17. Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, et al. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget 2013;4:163-73.
18. Ming SH, Sun TY, Xiao W, Xu XM. Matrix metalloproteinases-2, -9 and tissue inhibitor of metallo-proteinase-1 in lung cancer invasion and metastasis. Chin Med J 2005;118:69-72.
19. Golubovskaya VM. Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem 2010;10:735-41.
20. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58.
21. Xu CX, Jin H, Shin JY, Kim JE, Cho MH. Roles of protein kinase B/ Akt in lung cancer. Front Biosci (Elite Ed) 2010;2:1472-84.
22. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol 2010;21 Suppl 7:789-92.
23. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009;69:7135-9.
24. Kuo L, Chang HC, Leu TH, Maa MC, Hung WC. Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 2006;207:729-34.
25. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-76.